Skip to main content

Table 1 Age, Gender, Race and Pulmonary Function of study patients

From: The effect of tiotropium therapy on markers of elastin degradation in COPD

PATIENT NUMBER AGE GENDER RACE STUDY FVC**
%Pred
FEV1**
%Pred
FEV1/FVC**
%
-1- 61 M C* Pre-Tio
1 mo post
2 mo post
77
91
77
47
53
47
46
44
46
-2- 79 F C* Pre-Tio
1 mo post
2 mo post
97
96
106
64
72
73
49
56
51
-3- 65 F AA* Pre-Tio
1 mo post
2 mo post
106
96
108
74
65
66
54
53
48
-4- 63 F C* Pre-Tio
1 mo post
2 mo post
92
107
100
41
52
45
46
48
46
-5- 65 F H* Pre-Tio
1 mo post
2 mo post
70
84
84
67
84
82
75
79
78
-6- 65 M A* Pre-Tio
1 mo post
2 mo post
56
49
51
49
49
52
66
75
78
-7- 64 M C* Pre-Tio
1 mo post
2 mo post
59
69
64
41
47
41
51
51
48
-8- 39 M C* Pre-Tio
1 mo post
2 mo post
52
69
62
24
30
29
30
35
38
-9- 57 F H* Pre-Tio
1 mo post
2 mo post
93
87
83
55
55
53
47
51
51
-10- 69 M AA* Pre-Tio
1 mo post
2 mo post
58
82
109
30
39
54
39
36
38
-11- 66 F C* Pre-Tio
1 mo post
2 mo post
97
103
90
62
60
58
49
45
48
-12- 59 M C* Pre-Tio
1 mo post
2 mo post
110
91
102
72
69
71
50
57
53
  1. * AA = African-American
  2. C = Caucasian
  3. H = Hispanic
  4. A = Asian
  5. ** FVC%Pred = Forced Vital Capacity % of predicted
  6. FEV-1%Pred = Forced Expiratory Volume in 1 second % of predicted.
  7. FEV-1/FVC% = absolute ratio as percent.